Logo

ZCMD

Zhongchao Inc.

ZCMD

Zhongchao Inc. • NASDAQ
$0.67 ▲ 3.08% (+0.02)
Market Cap $3.10 M
52w High $2.50
52w Low $0.54
Dividend Yield 0%
P/E -3.51
Volume 19.43K
Outstanding Shares 4.65M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $5.601M ▼ $3.589M ▼ $-965.254K ▼ -17.233% ▼ $-0.038 ▲ $-460.213K ▼
Q4-2024 $7.516M ▼ $4.464M ▼ $-733.276K ▼ -9.756% ▼ $-0.16 ▼ $53.541K ▼
Q2-2024 $8.348M ▼ $4.789M ▼ $90.047K ▲ 1.079% ▲ $0.034 ▲ $303.978K ▲
Q4-2023 $9.058M ▼ $5.039M ▼ $-6.614M ▼ -73.024% ▼ $-2.54 ▼ $-7.872M ▼
Q2-2023 $10.376M $8.883M $-4.722M -45.504% $-1.81 $-4.646M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $15.034M ▲ $26.307M ▲ $2.559M ▲ $20.268M ▼
Q4-2024 $13.084M ▲ $25.885M ▲ $1.734M ▼ $20.838M ▲
Q2-2024 $12.221M ▼ $24.033M ▼ $3.314M ▼ $17.666M ▼
Q4-2023 $13.447M ▲ $24.417M ▼ $3.378M ▲ $18.007M ▼
Q2-2023 $12.223M $30.526M $3.354M $24.288M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-965.254K ▼ $1.821M ▲ $-980.271K ▼ $0 ▼ $1.071M ▼ $1.821M ▲
Q4-2024 $-733.276K ▼ $-2.283M ▼ $-10.089K ▲ $3.838M ▲ $1.561M ▲ $-3.233M ▼
Q2-2024 $90.047K ▲ $809.598K ▼ $-1.798M ▲ $0 $-1.269M ▲ $-1.286M ▼
Q4-2023 $-3.307M ▲ $1.907M ▲ $-5.693M ▼ $0 ▲ $-3.738M ▼ $1.08M ▲
Q2-2023 $-4.722M $-1.853M $1.939M $-159.58K $-233.632K $-1.865M

Five-Year Company Overview

Income Statement

Income Statement Zhongchao is operating at a very small scale, with revenue that has stayed roughly flat over the past several years. The business appears to hover around break-even, with only modest profits or small losses and no clear pattern of strong growth. Earnings per share have swung sharply, but this seems driven more by the company’s tiny size and share structure changes than by meaningful shifts in the underlying business. Overall, the income statement suggests a company that has yet to convert its platform strategy into visible, sustained growth or durable profitability.

Balance Sheet

Balance Sheet The balance sheet is light but relatively clean. Assets and equity are modest and have not grown much, which signals limited internal value creation so far, but the absence of debt reduces financial risk and interest burden. Cash balances appear adequate for a small, asset‑light business, yet not large enough to be a major strategic cushion. In short, the company is small but not highly leveraged, with limited room for large, self-funded expansion.

Cash Flow

Cash Flow Reported cash flow figures sit roughly around break-even, with little sign of strong or growing cash surpluses. Capital spending appears very low, consistent with an asset‑light, platform and content‑driven model. The flip side is that, without clear positive and rising operating cash flow, the business does not yet show evidence of strong monetization of its user base and partnerships. The limited detail also adds uncertainty around the true quality and stability of cash generation.

Competitive Edge

Competitive Edge Zhongchao occupies a niche in China’s healthcare information and education space, serving doctors, patients, and the general public through a set of connected online platforms. Its focus on high-need areas like oncology and rare diseases, together with relationships with hospitals, associations, and global pharmaceutical companies, gives it credibility and some barriers to entry. The ecosystem approach—linking professional training, public health education, and patient management—creates differentiation that is not trivial to copy. However, the company’s small scale in a large and competitive digital health market means it likely faces intense pressure from better-resourced platforms and constant need to prove its value to partners.

Innovation and R&D

Innovation and R&D Innovation centers on software, data, and content rather than heavy physical R&D. Zhongchao has developed specialized platforms (for doctors, patients, and the public) and is layering in artificial intelligence for content creation, patient interaction, and medical education through tools like its “E-Class” and disease-specific management systems. Its patient management offerings, especially in cancer and rare diseases, try to tackle real gaps in adherence and care coordination. The key question is less about ideas—where the company looks active—and more about execution: scaling usage, translating AI features into better outcomes and engagement, and turning these into dependable revenue streams.

Summary

Zhongchao is a small, asset‑light healthcare information platform player with a clean but modest balance sheet and income statements that show limited growth and fragile profitability. Strategically, it is positioned in attractive, specialized parts of China’s healthcare market and has built an integrated ecosystem with visible partners and early use of AI, which together provide some differentiation. At the same time, the business remains tiny relative to the market opportunity, with flat revenues and no strong track record of cash generation, which heightens uncertainty. Going forward, the key factors to watch are whether the company can grow its top line meaningfully, improve the consistency of its profits and cash flows, deepen pharmaceutical and institutional partnerships, and demonstrate that its AI‑driven platforms can scale in a competitive and regulated environment.